Exclusively for subscribers of Clinical Leader, our content collections bundle articles centered around a particular topic or theme. These carefully curated selections feature content from both our internal team of editors as well as our subject matter experts who contribute regularly to the site.
Patient recruitment and retention continue to hamper clinical trials, causing delays in start up and forcing some studies to be cancelled altogether. Approximately 50 percent of trials have delays in recruitment, costing companies an estimated $600,000 per day. In this free collection of articles, our experts from pharma discuss the actions you can and should be taking to make trials more patient centric.
Learn how technology investments can help with study start-up, how you can ensure a smooth start-up in a gene-therapy trial, and what companies are doing to overcome these challenges. I hope these articles help you to better navigate all of your trial start-ups.
While CRO selection and partnering may not be a hot and trending topic for some companies, the executives I talk to from the small- and mid-sized companies often list it as one of their biggest challenges. Finding the right CRO, putting the right contract in place, and becoming valued partners for each other is never easy. For everyone who deals with CRO selection and collaboration, we have produced this eBook. The articles included will provide you with the information you need to make better selections, avoid outsourcing mistakes, be a sponsor of choice, and make any partnership work better. I hope you enjoy them.
As chief editor for Clinical Leader, I speak to a lot of executives at companies working in the rare disease space. Clinical trials always present challenges to sponsor companies. Those challenges can be magnified greatly when dealing with rare and orphan diseases. The lack of a natural history of the disease is the first hurdle many companies have to navigate, but patient recruitment, data collection, and trial design can also present additional challenges that must be overcome. In this eBook, we present the stories of four companies attempting to overcome these challenges and bring effective therapies to patients in need.
The data gathered by researchers during a clinical trial might be sufficient to garner a regulatory approval, but it does not provide sponsor companies with a holistic view of how the drug will perform when made available to the general public. The small number of patients participating in trials, coupled with the lack of diversity present in those populations, makes it difficult to understand all of the effects a treatment will have in patients. For that reason, real-world evidence (RWE) has been gaining in popularity. In this eBook, we take a close look at RWE. What is it, how is it being used, why all the hype over it, and how the use of RWE is bringing together the worlds of pharma R&D and healthcare.
Clinical trials are changing. Companies continue to struggle with patient recruitment and the high cost and lengthy timelines of conducting clinical trials. Even once we recruit patients, keeping them engaged with the study can be a challenge. The lack of real-time monitoring of patients participating in trials also prevents researchers from having the quality data they need. This has led many in the industry to realize that we can’t conduct trials of the future using technologies of the past. One of the emerging trends that will enable trials of the future and make them better for patients is the emergence of digital health and wearable devices. In this eBook, we present seven articles showing the potential of these technologies to reform clinical trials.